Zilia’s Breakthrough Eye Care Technology Gets Health Canada Nod
QUEBEC CITY, June 19, 2025 – Canadian health technology company Zilia has achieved a significant milestone with Health Canada’s approval of its flagship product, the Zilia Ocular. This revolutionary retinal camera, developed in Quebec City, is the world’s first device authorized to measure oxygen saturation in the eye, marking a major breakthrough in eye care.
The Zilia Ocular features patented optical technology that enables non-invasive measurement of oxygenation in the eye. This metabolic biomarker provides eye care professionals with a new tool to assess the physiological state of the eye, potentially detecting issues before structural damage occurs. “This represents a true paradigm shift,” said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. “By measuring retinal oxygenation in real-time, we aim to help clinicians detect and manage eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration more effectively.”
The approval positions Zilia at the forefront of oculomics, an emerging field that uses the eye as a gateway to assess overall health. As this field gains global traction, biomarkers like oxygen saturation are paving the way for a more preventive, personalized, and data-driven approach to medicine. Zilia plans to launch its device in Canada in the coming months, followed by expansion into the United States and Europe.
About Zilia
Zilia is a health technology company developing a groundbreaking platform to non-invasively measure biomarkers in the eye, with an initial focus on ocular oximetry. By integrating advanced photonics and artificial intelligence, Zilia’s first-of-kind technology aims to leverage the eye’s optical properties and direct connections to the vascular system and the brain to capture critical information on ocular and overall health.
For more information, visit Zilia’s website.
